Your browser doesn't support javascript.
Blocking TNF signaling may save lives in COVID-19 infection.
Ablamunits, Vitaly; Lepsy, Christopher.
  • Ablamunits V; Biomedicine Design, Pfizer Inc, 1 Burtt Rd, G2002, Andover, MA, 01810, US. vitaly.ablamunits@pfizer.com.
  • Lepsy C; Biomedicine Design, Pfizer Inc, 1 Burtt Rd, G2002, Andover, MA, 01810, US.
Mol Biol Rep ; 49(3): 2303-2309, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1648443
ABSTRACT
Global vaccination effort and better understanding of treatment strategies provided a ray of hope for improvement in COVID-19 pandemic, however, in many countries, the disease continues to collect its death toll. The major pathogenic mechanism behind severe cases associated with high mortality is the burst of pro-inflammatory cytokines TNF, IL-6, IFNγ and others, resulting in multiple organ failure. Although the exact contribution of each cytokine is not clear, we provide an evidence that the central mediator of cytokine storm and its devastating consequences may be TNF. This cytokine is known to be involved in activated blood clotting, lung damage, insulin resistance, heart failure, and other conditions. A number of currently available pharmaceutical agents such as monoclonal antibodies and soluble TNF receptors can effectively prevent TNF from binding to its receptor(s). Other drugs are known to block NFkB, the major signal transducer molecule used in TNF signaling, or to block kinases involved in downstream activation cascades. Some of these medicines have already been selected for clinical trials, but more work is needed. A simple, rapid, and inexpensive method of directly monitoring TNF levels may be a valuable tool for a timely selection of COVID-19 patients for anti-TNF therapy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / Cytokine Release Syndrome / Tumor Necrosis Factor Inhibitors / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Mol Biol Rep Year: 2022 Document Type: Article Affiliation country: S11033-022-07166-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / Cytokine Release Syndrome / Tumor Necrosis Factor Inhibitors / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Mol Biol Rep Year: 2022 Document Type: Article Affiliation country: S11033-022-07166-x